GlycoVaxyn AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Private, Subsidiary
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.glycovaxyn.com
Vaccine Against Escherichia Coli Infection
Phase 1
Completed
- Conditions
- E.Coli Infections
- Interventions
- Biological: PlaceboBiological: E.coli bioconjugate vaccine
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- GlycoVaxyn AG
- Target Recruit Count
- 194
- Registration Number
- NCT02289794
- Locations
- 🇨🇭
Hôpitaux Universitaires de Genève, Geneve, GE, Switzerland
Safety and Reactogenicity of Bioconjugate Vaccine to Prevent Shigella
Phase 1
Completed
- Conditions
- Shigellosis
- Interventions
- Biological: Shigella vaccine
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- GlycoVaxyn AG
- Target Recruit Count
- 40
- Registration Number
- NCT01069471
- Locations
- 🇨🇭
Institute of Social and Preventive Medicine, Zurich, Switzerland
© Copyright 2025. All Rights Reserved by MedPath